RECURSION PHARMACEUTICALS INC CLAS (RXRX) competitors & alternatives
Health Care · NASDAQ
RECURSION PHARMACEUTICALS INC CLAS (RXRX)'s top competitors and alternatives — its most similar public companies — include SCHRODINGER INC (SDGR), PRELUDE THERAPEUTICS INC (PRLD), NURIX THERAPEUTICS INC (NRIX), RAPPORT THERAPEUTICS INC (RAPP), NEUMORA THERAPEUTICS INC (NMRA), MONTE ROSA THERAPEUTICS INC (GLUE), ORIC PHARMACEUTICALS INC (ORIC), CYTOMX THERAPEUTICS INC (CTMX), DYNE THERAPEUTICS INC (DYN), NAUTILUS BIOTECHNOLGY INC (NAUT), DAMORA THERAPEUTICS INC (DMRA) and PRECIGEN INC (PGEN). These are RECURSION PHARMACEUTICALS INC CLAS's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top RXRX competitors & alternatives
-
SCHRODINGER INCSDGRHealth Care
Physics-based computational platform that accelerates drug discovery and materials science by predicting molecular properties with high accuracy, enabling…
$15.03 (as of 2026-07-22) · market cap $1.1B
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
NEUMORA THERAPEUTICS INCNMRAHealth Care
Neumora Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for psychiatric and neurodegenerative brain disorders.
$1.54 (as of 2026-07-22) · market cap $298M
-
MONTE ROSA THERAPEUTICS INCGLUEHealth Care
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its…
$23.79 (as of 2026-07-22) · market cap $2.0B
-
ORIC PHARMACEUTICALS INCORICHealth Care
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
$10.75 (as of 2026-07-22) · market cap $1.1B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
DYNE THERAPEUTICS INCDYNHealth Care
Dyne Therapeutics is a clinical-stage biotechnology company leveraging its proprietary FORCE platform to develop targeted therapies for serious,…
$23.21 (as of 2026-07-22) · market cap $3.8B
-
NAUTILUS BIOTECHNOLGY INCNAUTHealth Care
A pre-commercial proteomics platform company developing Iterative Mapping technology to enable single-molecule protein counting for comprehensive, reproducible…
$1.70 (as of 2026-07-22) · market cap $216M
-
DAMORA THERAPEUTICS INCDMRAHealth Care
Damora Therapeutics is a biotechnology company developing a pipeline of precision antibody therapies specifically targeting mutCALR-driven myeloproliferative…
$29.99 (as of 2026-07-22) · market cap $1.8B
-
PRECIGEN INCPGENHealth Care
Gene therapy precision medicine company with FDA-approved adenoviral immunotherapy for HPV-driven respiratory disease and a development pipeline of CAR-T and…
$5.32 (as of 2026-07-22) · market cap $1.9B
Not quite? Describe exactly what you want →
Peers are RECURSION PHARMACEUTICALS INC CLAS's closest public companies by shared sub-industry, sector and business themes. See the full profile: RECURSION PHARMACEUTICALS INC CLAS (RXRX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.